Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Background: Limited clinical data exists regarding use of direct oral anticoagulants (DOACs)
in extreme obesity, specifically those≥ 140 kg or having a body mass index (BMI)≥ 50 …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Patients with high body weight are at increased risk of developing atrial fibrillation (AF) or
venous thromboembolism (VTE) and are often treated with antithrombotic drugs. 1 Direct …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Abstract Background Direct oral anticoagulants (DOACs) are recommended in preference to
traditional anticoagulants (LMWH±warfarin) for treating acute venous thromboembolism …

The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin
remains uncertain in obese patients. We assessed the comparative effectiveness and safety …

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …